XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 27, 2020
Aug. 31, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Accounts receivable     $ 6,938     $ 6,013
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Proceeds from collaborators   $ 75,000        
Collaborative arrangement transaction price $ 95,100          
License fee 75,000          
Collaborative arrangement estimated reimbursable service costs 20,100          
Accounts receivable     1,900     1,900
Deferred revenue     33,900     $ 40,900
Financial advisory fees         $ 1,500  
Percent of initial recognition         2.00%  
Amortization     $ 100 $ 100    
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Development and sales-based milestone payments to be received 420,000          
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement | Achievement Of Commercial Milestones            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Development and sales-based milestone payments to be received $ 300,000